The Federal Government of Nigeria has confirmed the arrival of the long-acting HIV prevention injection, Lenacapavir, marking a significant step in broadening the country’s HIV prevention strategies.
The announcement was made in a statement signed by Adebobola Bashorun National Coordinator”], the National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), on Wednesday, March 11, 2026.
Bashorun emphasised that the introduction of Lenacapavir reflects Nigeria’s commitment to innovative, evidence-based approaches to reduce new HIV infections.
“NASCP, in collaboration with partners and stakeholders, will work to ensure the safe introduction, strategic deployment, and effective integration of Lenacapavir into the national HIV prevention options,” he said.
He added that the rollout will support ongoing efforts to increase access to prevention services and strengthen Nigeria’s broader HIV response.
Developed by Gilead Sciences, Lenacapavir is a long-acting injectable administered twice a year, offering a more convenient alternative to daily oral preventive medications. Health authorities say its introduction for pre-exposure prophylaxis (PrEP) is a major step toward expanding HIV prevention choices for individuals at risk.
Bashorun further stated, “The arrival of Long-Acting Injectable Lenacapavir is a clear demonstration of Nigeria’s resolve to scale up innovative solutions and strengthen the fight against HIV. Together, Nigeria moves closer to ending HIV as a public health threat.”
